SCHEMBL6496929

SCHEMBL6496929

CC(C)(C)OC(=O)N1CCN(c2ccc(NC(=O)C3=C(c4ccc(C(F)(F)F)cc4)CCCC3)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
SMN1; SMN2 Q16637 5/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
TSHR P16473 1/20 0.55
NAMPT P43490 1/20 0.50
CYP2C19 P33261 1/20 0.46
GPR119 Q8TDV5 1/20 0.46
HTT P42858 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTR1A P08908 1/20 0.45
HTR1D P28221 1/20 0.45
HTR1B P28222 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
HTR6 P50406 1/20 0.45
LMNA P02545 3/20 0.45
MAPKAPK2 P49137 1/20 0.45
DGAT1 O75907 1/20 0.45
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488746 0.90 MAPT (0.60) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL6531877 0.87 SMN1; SMN2 (0.54) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL6500327 0.86 NR1H2 (0.45) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL6680389 0.83 MAPKAPK2 (0.46) MAPTSMN1; SMN2MEN1KMT2ANAMPT
SCHEMBL6488027 0.82 ESR2 (0.50) MAPTNAMPTESR2NPC1
SCHEMBL6496056 0.82 MAPKAPK2 (0.66) MAPTSMN1; SMN2HTTLMNAMAPKAPK2
SCHEMBL6489848 0.82 CCNC (0.44) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL24989582 0.81 MAPT (0.60) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL6698710 0.81 MAPT (0.56) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL6490755 0.80 CA1 (0.51) MAPTLMNAMAPKAPK2TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MAPT 4202/4885SMN1; SMN2 1921/4885MEN1 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.